Normal view MARC view ISBD view

Summary of the 2018 Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) for transcatheter aortic valve replacement. [Review]

MedStar author(s):

Citation: Cardiovascular Revascularization Medicine. 19(8):964-970, 2018 12.PMID: 30344056Institution: MedStar Heart & Vascular InstituteForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Advisory Committees | *Aortic Valve Stenosis/su [Surgery] | *Centers for Medicare and Medicaid Services (U.S.) | *Registries | *Transcatheter Aortic Valve Replacement/ec [Economics] | Aortic Valve Stenosis/ec [Economics] | Humans | United StatesYear: 2018 Local holdings: Available in print through MWHC library: 2002 - presentISSN:

1878-0938

Name of journal: Cardiovascular revascularization medicine : including molecular interventionsAbstract: Copyright (c) 2018 Elsevier Inc. All rights reserved.Medicare coverage for transcatheter aortic valve replacement (TAVR) in the United States (US) is governed by the 2012 National Coverage Determination (NCD 20.32), which enshrined minimum numbers of TAVR, surgical aortic valve replacement, and percutaneous coronary intervention that centers must perform to begin or maintain TAVR programs. In July 2018, the Centers for Medicare and Medicaid Services (CMS) convened a meeting of the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) to review the evidence for setting minimum procedure volume requirements and to evaluate the impact of such requirements on access to care. In this paper, we summarize the MEDCAC panel deliberations, the evidence presented to the panel, and how the panel members voted. CMS is expected to publish a draft decision in March 2019 that may reshape the TAVR landscape in the US for years to come.All authors: Edelman JJ, Khan JM, Rogers T, Waksman RFiscal year: FY2019Digital Object Identifier:

https://dx.doi.org/10.1016/j.carrev.2018.10.009

Date added to catalog: 2018-11-02

Holdings ( 1 )
Title notes ( 4 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	30344056	Available		30344056

Available in print through MWHC library: 2002 - present

Medicare coverage for transcatheter aortic valve replacement (TAVR) in the United States (US) is governed by the 2012 National Coverage Determination (NCD 20.32), which enshrined minimum numbers of TAVR, surgical aortic valve replacement, and percutaneous coronary intervention that centers must perform to begin or maintain TAVR programs. In July 2018, the Centers for Medicare and Medicaid Services (CMS) convened a meeting of the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) to review the evidence for setting minimum procedure volume requirements and to evaluate the impact of such requirements on access to care. In this paper, we summarize the MEDCAC panel deliberations, the evidence presented to the panel, and how the panel members voted. CMS is expected to publish a draft decision in March 2019 that may reshape the TAVR landscape in the US for years to come.

English